The Intra- Cellular Therapies is a biopharmaceutical company. It is also known as ICTI. The main focus of this company on the discovery and clinical development of innovation. This discovery is made for neuropsychiatric and neurological disorders with the central Nervous system. The lead product is ITI-007 and it’s the first-class treatment for Schizophrenia.
The main work of Intra- Cellular Therapies, Inc. (NASDAQ: ITCI) main focused on biopharmaceutical development and commercialization of therapeutics for nervous system disorders. The ITCI stock at https://www.webull.com/newslist/nasdaq-itci also announced its first-quarter financial result and also provide its corporate update.
The Comprehensive promotional activities for CAPLYTA follow the approval of the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenic in adults in December 2019. They did two trials and show the benefits over placebo on the primary endpoint which is positive and negative on PANSS total score. As per the short time studies the baseline weight change from the mean, fasting glucose, triglycerides, and total cholesterol with a similar CAOLYTA and Placebo.
It also successfully complete its national launch meeting which was 100% virtual and in the first quarter of 2020 it also higher some neuroscience sales specialists because they have sale experience including antipsychotics. After this meeting all the sale specialist are engaging with health care and their main goal is providing comprehensive education on CAPLYTA.
The sale specialist of ICTI have also had remote product presentation and sampling capability and these activities are also complemented by the virtual peer to peer medical education and some outreach program.
It also launches new comprehensive patient support which is designed for the eligible CAPLYSTA patients. It covers their coverage and reimbursement services of the patients. The manufacturing and chain supply are related to the commercial demand for CAPLYTA.
The ITCI also have substantial product supply in the U.S. To meet with expected demand. The share value of ICTI stock is high in 2020 in comparison with 2019. The COVID -19 does not impact ICTI.
The Investor is still investing in the ITCI Stock and also earning a good amount on their investment. It’s offering 11.5 million shares to the public and the market value of the stock increased by $ 399.5 million in gross proceeds.
In 2019, the share value of ICTI was not high and the company faces loss but after approval from the caplet, the balance sheet of ICTI was in good condition. The ICTI share market value also increases. Every year many investors invest in it for higher revenue. If you want to know more stock trading appintroduce, you can visit at https://www.webull.com/introduce.